dr. rugo discusses the equivalency of trastuzumab biosimilars
Published 5 years ago • 128 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
1:53
dr. rugo discusses a comparative review of trastuzumab biosimilars
-
1:37
dr. rugo discusses the regulatory process behind biosimilars
-
1:30
dr. hope rugo on trastuzumab biosimilar in her2-positive breast cancer
-
0:59
dr. hope rugo on safety of trastuzumab biosimilar for her2 breast cancer
-
3:38
biosimilar trastuzumab
-
1:00
dr. dang on the significance of the myl-1401o biosimilar in her2-positive metastatic breast cancer
-
2:00
dr. rugo discusses advancements with biosimilars
-
1:41
dr. pegram on the development of trastuzumab biosimilars
-
0:51
dr. jhaveri on the use of trastuzumab biosimilars in breast cancer
-
0:59
dr. verma discusses biosimilars for trastuzumab
-
1:15
dr. rugo discusses the future of angiogenesis in breast cancer
-
3:18
trial of proposed trastuzumab biosimilar, myl-1401o vs herceptin
-
1:47
the use of trastuzumab and biosimilars in the treatment of breast cancer
-
12:12
breast cancer treatment - trastuzumab biosimilars
-
0:55
dr. rugo on the future of extended adjuvant hormone therapy for breast cancer
-
3:49
novel strategies for her2 metastatic breast cancer; biosimilars
-
1:01
dr. brufsky on trastuzumab biosimilars in breast cancer
-
6:25
hope s. rugo, et al.
-
2:35
dr. rugo on the phase iii sophia trial in her2 breast cancer